Characterisation and glucoregulatory actions of a novel acylated form of the (Pro3)GIP receptor antagonist in type 2 diabetes

Biological Chemistry

Volumn 388, Issue 2, 2007, Pages 173-179

  Gault, Victor A ^a   Hunter, Kerry ^a   Irwin, Nigel ^a   Greer, Brett ^b   Green, Brian D ^b   Harriott, Patrick ^b   O'Harte, Finbarr P M ^a   Flatt, Peter R ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Antihyperglycaemic activity; DPP IV; Fatty acid linked peptides; GIP receptor antagonists; Insulin secretion; Obese diabetic (ob ob) mice

Indexed keywords

CYCLIC AMP; GASTRIC INHIBITORY POLYPEPTIDE; GLUCOSE; INSULIN; PALMITIC ACID;

ACYLATION; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; IN VIVO STUDY; INSULIN RELEASE; INSULIN SENSITIVITY; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TEST MEAL;

ACYLATION; ANIMALS; BINDING SITES; CYCLIC AMP; DIABETES MELLITUS, TYPE 2; GASTRIC INHIBITORY POLYPEPTIDE; GLUCOSE; INSULIN; LYSINE; MICE; MICE, OBESE; PALMITIC ACID; RECEPTORS, GASTROINTESTINAL HORMONE; STRUCTURE-ACTIVITY RELATIONSHIP; TIME FACTORS;

MUS;

EID: 33846575255     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/BC.2007.019     Document Type: Article

References (20)

1. Bailey, C.J. and Flatt, P.R. (1982). Influence of genetic background and age on the expression of the obese hyperglycaemic syndrome in Aston ob/ob mice. Int. J. Obesity 6, 11-21.
2. Burington, R.S. (1973). Handbook of Mathematical Tables and Formulae (New York, USA: McGraw-Hill).
3. Deacon, C.F., Nauck, M.A., Meier, J.J., Hucking, K., and Holst, J.J. (2000). Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J. Clin. Endocrinol. Metab. 85, 3575-3581.
4. Flatt, P.R. and Bailey, C.J. (1981). Abnormal plasma glucose and insulin responses in heterozygous lean (ob/+) mice. Diabetologia 20, 573-577.
5. Gault, V.A., O'Harte, F.P.M., Harriott, P., and Flatt, P.R. (2002). Characterization of the cellular and metabolic effects of a novel enzyme-resistant antagonist of glucose-dependent insulinotropic polypeptide. Biochem. Biophys. Res. Commun. 290, 1420-1426.
6. Gault, V.A., O'Harte, F.P.M., and Flatt, P.R. (2003a). Glucose-dependent insulinotropic polypeptide (GIP): anti-diabetic and anti-obesity potential? Neuropeptides 37, 253-263.
7. 3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin. Diabetologia 46, 222-230.
8. 3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes. Diabetes 54, 2436-2446.
9. Gedulin, B.R., Smith, P., Prickett, K.S., Tryon, M., Barnhill, S., Reynolds, J., Nielsen, L.L., Parkes, D.G., and Young, A.A. (2005). Dose-response for glycaemic and metabolic changes 28 days after single injection of long-acting release exenatide in diabetic fatty Zucker rats. Diabetologia 48, 1380-1385.
10. 8-substituted GLP-1 analogues. Biol. Chem. 385, 169-177.
11. Gremlich, S., Porret, A., Hani, E.H., Cherif, D., Vionnet, N., Froguel, P., and Thorens, B. (1995). Cloning, functional expression, and chromosomal localization of the human pancreatic islet glucose-dependent insulinotropic polypeptide receptor. Diabetes 44, 1202-1208.
12. Irwin, N., Gault, V.A., Green, B.D., Greer, B., McCluskey, J.T., Harriott, P., O'Harte, F.P.M., and Flatt, P.R. (2004). Effects of short-term chemical ablation of the GIP receptor on insulin secretion, islet morphology and glucose homeostasis in mice. Biol. Chem. 385, 845-852.
13. Juhl, C.B., Hollingdal, M., Sturis, J., Jakobsen, G., Agerso, H., Veldhuis, J., Porksen, N., and Schmitz, O. (2002). Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes 51, 424-429.
14. Kurtzhals, P., Havelund, S., Jonassen, I., Kiehr, B., Larsen, U., Riebel, U., and Markussen, J. (1995). Albumin-binding of insulins acylated with fatty acids - characterisation of the ligand protein-interactions and the correlation between binding-affinity and the timing of the insulin effect in vivo. Biochem. J. 312, 725-731.
15. Markussen, J., Havelund, S., Kurtzhals, P., Andersen, A.S., Halstøm, J., Hasselager, E., Larsen, U.D., Riebel, U., Schaffer, L., Vad, K., and Jonassen, I. (1996). Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs. Diabetologia 39, 281-288.
16. McClenaghan, N.H., Barnett, C.R., Ah-Sing, E., Abdel-Wahab, Y.H.A., O'Harte, F.P.M., Yoon, T.W., Swanston-Flatt, S.K., and Flatt, P.R. (1996). Characterisation of a novel glucose-responsive insulin-secreting cell line, BRIN BD11, produced by electrofusion. Diabetes 45, 1132-1140.
17. Meier, J.J., Nauck, M.A., Schmidt, W.E., and Gallwitz, B. (2002). Gastric inhibitory polypeptide: the neglected incretin revisited. Regul. Pept. 107, 1-13.
18. Meier, J.J., Nauck, M.A., Kranz, D., Holst, J.J., Deacon, C.F., Gaeckler, D., Schmidt, W.E., and Gallwitz, B. 2004. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes 53, 654-662.
19. Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., et al. (2002). Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat. Med. 8, 738-742.
20. Stevens, J.F. (1971). Determination of glucose by an automatic analyser. Clin. Chem. Acta 32, 199-201.